Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.

Du L, Li X, Zhen L, Chen W, Mu L, Zhang Y, Song A

DOI: 10.3892/mmr.2018.8769
Published: 2018 May
Container: Molecular medicine reports
Publisher: Not recorded
Open access: yes

Credibility signals

serious concern Score 10/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
serious concernRetraction Watch retraction: 1 retraction notice matched this DOI. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3892/mmr.2018.8769,
  title = {Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.},
  author = {Du L and Li X and Zhen L and Chen W and Mu L and Zhang Y and Song A},
  year = {2018},
  journal = {Molecular medicine reports},
  doi = {10.3892/mmr.2018.8769},
  url = {https://doi.org/10.3892/mmr.2018.8769}
}

RIS

TY  - JOUR
TI  - Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.
AU  - Du L
AU  - Li X
AU  - Zhen L
AU  - Chen W
AU  - Mu L
AU  - Zhang Y
AU  - Song A
PY  - 2018
JO  - Molecular medicine reports
DO  - 10.3892/mmr.2018.8769
UR  - https://doi.org/10.3892/mmr.2018.8769
ER  -

APA

L, D., X, L., L, Z., W, C., L, M., Y, Z., & A, S. (2018). Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.. Molecular medicine reports. https://doi.org/10.3892/mmr.2018.8769

Source records

pubmed · retrieved 2026-09-24T19:26:26.999Z